Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 17;15(1):67.
doi: 10.1038/s41408-025-01275-z.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

Lucía Pérez-Lamas #  1 , Adrián Segura Diaz #  2 , Regina García Delgado  3 , Alberto Álvarez-Larrán  4   5 , María Alicia Senin  6 , Elvira Mora  7 , María Laura Fox  8 , Irene Pastor Galan  9 , Gemma Azaceta  10 , Sara Garrido Paniagua  8 , Raúl Pérez Lopez  11 , Diana Margarita Trejos Carvajal  12 , Anna Angona  13 , Carmen Albo López  14 , Pablo Lorente Alegre  15 , Miriam Vara  16 , Juan Antonio Vera Goñi  17 , Dunia De Miguel Llorente  18 , Ángeles Fernández Rodríguez  19 , Alberto Marín Sanchez  20 , Adriana Hernando Megido  21 , María Teresa Gómez Casares  2 , Ruth Stuckey  2 , Gonzalo Carreño-Tarragona  22 , Natalia De Las Heras Rodriguez  23 , Blanca Xicoy  24 , Manuel Pérez Encinas  25 , Raquel Mata Serna  26 , Lucia Núñez Martin-Buitrago  27 , Francisca Ferrer Marín  28 , Neus Amer Salas  29 , Carolina Guillén Rienda  30 , Patricia Velez  31 , Laura Lamarca Eraso  32 , Sandra Martín  33 , Iryna Luts Khoroz  34 , Erik De Cabo López  35 , Angela Gil  18 , Sofía Martín-Consuegra Ramos  36 , Fernando Marco De Lucas  37 , María José Otero Martinez-Fornes  38 , María Luisa Martín Mateos  39 , Teresa Arquero  26 , Elena Cabezudo Pérez  40 , Luis Antonio López Gómez  41 , Ángela Martínez Hellin  42 , Aurelia Tejedor  43 , Esther Herrera de Pablo  44 , María Isabel Mata Vazquez  45 , Inmaculada Castillo Valero  46 , María José Fernández  47 , Carlos Aguilar  48 , Marta Santaliestra  49 , Antonio García Menchon  50 , Begoña Navas Elorza  51 , María Antonia Duran  52 , María Pérez Sala  53 , Teresa Hernández Santamaría  54 , Ma Ángeles Muñoz Jarreño  55 , Julio Dávila-Valls  56 , Williana Torres Jiménez  57 , Joan Alfons Gonzálvez Fernández  58 , Hugo Alexander Torres Mantilla  59 , Teresa Cobo Rodríguez  60 , Aitor Abuin Blanco  61 , Francisco Pérez  62 , Santiago Osorio Prendes  63 , Paola Beneit Villena  64 , Raisa Peralta  65 , Federico Herrera  66 , Eloi Cañamero Giro  67 , Reyes Jiménez Bárcenas  68 , Mercedes Gasior Kabat  69 , Sonia González De Villambrosia  70 , Mariana Teresa Tercero-Mora Rodriguez  71 , Marina Menéndez Cuevas  72 , Beatriz Cuevas Ruiz  73 , Marta Fonseca-Santos  39 , Sonia Garcés Piquer  74 , Rosalía De La Puerta  75 , Álvaro Lorenzo Vizcaya  61 , Juan Carlos Hernández Boluda  76 , Valentín García Gutiérrez  77
Affiliations

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

Lucía Pérez-Lamas et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: LPL: Novartis, Incyte and GSK; travel grants. GSK and Novartis speaker honoraria. AAL: honoraria fees for participating in advisory board from AOP and for lectures from Novartis and GSK. RJB: Novartis, GSK; speaker honoraria. VGG: Novartis; BMS; Incyte; Pfizer and GSK; travel grants, research funding, advisory board. ASD: Novartis; BMS; Incyte and Pfizer; travel grants. Novartis; research funding, advisory board. JCHB: advisory honoraria from Incyte, GSK, Novartis, Pfizer, BMS, and AOP Health; travel support from Incyte and Pfizer; speaker fees from GSK, Novartis, Pfizer, and Incyte. Ethics approval and consent to participate: The study received approval from the Ramón y Cajal Hospital Ethics Committee (code number 176/24) and the GEMFIN Scientific Committee, and adhered to ethical standards for medical research involving human subjects. The study was conducted in accordance with the Declaration of Helsinki and other relevant guidelines and regulations. Written informed consent was obtained from all participants.

Figures

Fig. 1
Fig. 1. Anemia Response in transfusion-dependent and non-transfusion-dependent patients, subdivided by prior exposure to JAKi (graphic version).
Patients with prior JAK inhibitor exposure are shown in red, naive patients are depicted in green. *The analysis included patients with anemia per the 2024 IWG-ELN criteria who had at least one month of follow-up for response evaluation. m: months, TDA: Transfusion-Dependent Anemia, JAKi: Janus Kinase Inhibitor.
See this image and copyright information in PMC

References

    1. Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J Hematol Oncol. 2023;16:82. - PMC - PubMed
    1. Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, et al. Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. Br J Haematol. 2021;195:244–8. - PMC - PubMed
    1. Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2024;11:e729–e740. - PubMed
    1. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2023;98:801–21. - PubMed
    1. Gupta V, Cerquozzi S, Foltz L, Hillis C, Devlin R, Elsawy M, et al. Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group. JCO Oncol Pr. 2020;16:351–9. - PMC - PubMed

LinkOut - more resources